259 related articles for article (PubMed ID: 35085819)
1. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use.
Spergel BL; Ruffner MA; Godwin BC; Liacouras CA; Cianferoni A; Gober L; Hill DA; Brown-Whitehorn TF; Chaiboonma K; Aceves SA; Muir AM; Spergel JM
Ann Allergy Asthma Immunol; 2022 May; 128(5):589-593. PubMed ID: 35085819
[TBL] [Abstract][Full Text] [Related]
2. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
[TBL] [Abstract][Full Text] [Related]
3. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
4. Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Colque-Bayona M; Hernández-Cano N; Tomás-Pérez M; Caballero T; Quirce S; Domínguez-Ortega J
J Asthma; 2024 Jul; 61(7):762-765. PubMed ID: 38152869
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Hamilton JD; Harel S; Swanson BN; Brian W; Chen Z; Rice MS; Amin N; Ardeleanu M; Radin A; Shumel B; Ruddy M; Patel N; Pirozzi G; Mannent L; Graham NMH
Clin Exp Allergy; 2021 Jul; 51(7):915-931. PubMed ID: 34037993
[TBL] [Abstract][Full Text] [Related]
6. Relapse of Eosinophilic Esophagitis on Dupilumab.
Buendia MA; Choksi YA; Hiremath G
JPGN Rep; 2022 Nov; 3(4):e273. PubMed ID: 37168482
[TBL] [Abstract][Full Text] [Related]
7. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis.
Lee CJ; Dellon ES
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):252-258. PubMed ID: 37660770
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.
Goyal R; Kamboj AK; Snyder DL
Mayo Clin Proc; 2024 Apr; 99(4):640-648. PubMed ID: 38569813
[TBL] [Abstract][Full Text] [Related]
10. Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center.
Syverson EP; Rubinstein E
JPGN Rep; 2022 May; 3(2):e180. PubMed ID: 37168913
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
Chehade M; Dellon ES; Spergel JM; Collins MH; Rothenberg ME; Pesek RD; Hirano I; Liu R; Laws E; Mortensen E; Martincova R; Shabbir A; McCann E; Kamal MA; Kosloski MP; Hamilton JD; Samuely C; Lim WK; Wipperman MF; Farrell A; Patel N; Yancopoulos GD; Glotfelty L; Maloney J
N Engl J Med; 2024 Jun; 390(24):2239-2251. PubMed ID: 38924731
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
[TBL] [Abstract][Full Text] [Related]
13. Clinical Evaluation of the Child with Eosinophilic Esophagitis.
Bauer M; Nguyen N; Liacouras CA
Immunol Allergy Clin North Am; 2024 May; 44(2):157-171. PubMed ID: 38575215
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement.
Becker R; Rigsby M; Suchi M; Lerner DG; Chugh A
J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1337-1341. PubMed ID: 38587127
[TBL] [Abstract][Full Text] [Related]
15. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
16. One Year Into Dupilumab: Physician and Patient Experiences in Initiating Dupilumab for Pediatric Eosinophilic Esophagitis.
Nguyen N; Burger C; Skirka S; White S; Smith M; Menard-Katcher C; Furuta GT; Mehta P
J Pediatr Gastroenterol Nutr; 2023 Oct; 77(4):536-539. PubMed ID: 37491718
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series.
Sia T; Bacchus L; Tanaka R; Khuda R; Mallik S; Leung J
Clin Transl Gastroenterol; 2024 Jan; 15(1):e00646. PubMed ID: 37753954
[TBL] [Abstract][Full Text] [Related]
18. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis.
Chromy D; Bartosik T; Brkic FF; Quint T; Tu A; Eckl-Dorna J; Schneider S; Bangert C
J Dermatol; 2023 Jan; 50(1):89-93. PubMed ID: 36177732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
